Nautilus Biotechnology (NASDAQ:NAUT) vs. ANGLE (OTCMKTS:ANPCY) Critical Analysis

ANGLE (OTCMKTS:ANPCY) and Nautilus Biotechnology (NASDAQ:NAUT) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Profitability

This table compares ANGLE and Nautilus Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANGLE	N/A	N/A	N/A
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Institutional & Insider Ownership

50.7% of Nautilus Biotechnology shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares ANGLE and Nautilus Biotechnology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANGLE	N/A	N/A	N/A	C($0.48)	-0.14
Nautilus Biotechnology	N/A	N/A	-$59.00 million	($0.45)	-1.97

Nautilus Biotechnology is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for ANGLE and Nautilus Biotechnology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANGLE	0	0	0	0	0.00
Nautilus Biotechnology	1	0	1	0	2.00

Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 351.62%. Given Nautilus Biotechnology’s stronger consensus rating and higher possible upside, analysts clearly believe Nautilus Biotechnology is more favorable than ANGLE.

Summary

Nautilus Biotechnology beats ANGLE on 6 of the 9 factors compared between the two stocks.

About ANGLE

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.